Literature DB >> 8016104

CDR1 T-cell receptor beta-chain peptide induces major histocompatibility complex class II-restricted T-T cell interactions.

C P Broeren1, M A Lucassen, M J van Stipdonk, R van der Zee, C J Boog, J G Kusters, W van Eden.   

Abstract

T-T cell interactions have been proposed in postulated network theories of immunoregulation and autoimmunity. Despite previous reports of protection induced by T-cell receptor (TcR)-derived peptides in experimental autoimmunity, no evidence for T-T cell interactions by direct recognition of processed TcRs on native T cells was obtained. Here we report that immunization of rats with overlapping sets of peptides of the TcR alpha or beta chain allowed us to detect immunogenic TcR peptides. Remarkably enough, these TcR peptides appeared to cluster within the hypervariable complementarity-determining regions of the TcR. Immunization of rats with these TcR peptides induced CD4+ TcR peptide-specific T cells, which recognized both rDNA TcR proteins and the original, arthritogenic T cell in a major histocompatibility complex class II-restricted way. These findings indicate that activated T cells can process and present their own TcR in the context of major histocompatibility complex class II molecules and, furthermore, that such peptides can be recognized by TcR variable gene-specific T cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8016104      PMCID: PMC44124          DOI: 10.1073/pnas.91.13.5997

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Development of arthritis, periarthritis and periostitis in rats given adjuvants.

Authors:  C M PEARSON
Journal:  Proc Soc Exp Biol Med       Date:  1956-01

2.  Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis.

Authors:  W van Eden; J E Thole; R van der Zee; A Noordzij; J D van Embden; E J Hensen; I R Cohen
Journal:  Nature       Date:  1988-01-14       Impact factor: 49.962

3.  Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis.

Authors:  A A Vandenbark; G Hashim; H Offner
Journal:  Nature       Date:  1989-10-12       Impact factor: 49.962

4.  Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein.

Authors:  A Ben-Nun; H Wekerle; I R Cohen
Journal:  Nature       Date:  1981-07-02       Impact factor: 49.962

5.  Conserved nucleotide sequences at the 5' end of T cell receptor variable genes facilitate polymerase chain reaction amplification.

Authors:  C P Broeren; G M Verjans; W Van Eden; J G Kusters; J A Lenstra; T Logtenberg
Journal:  Eur J Immunol       Date:  1991-03       Impact factor: 5.532

6.  Autoimmune encephalomyelitis (EAE) mediated or prevented by T lymphocyte lines directed against diverse antigenic determinants of myelin basic protein. Vaccination is determinant specific.

Authors:  J Holoshitz; A Frenkel; A Ben-Nun; I R Cohen
Journal:  J Immunol       Date:  1983-12       Impact factor: 5.422

7.  Arthritis induced in rats by cloned T lymphocytes responsive to mycobacteria but not to collagen type II.

Authors:  J Holoshitz; A Matitiau; I R Cohen
Journal:  J Clin Invest       Date:  1984-01       Impact factor: 14.808

8.  Human T cell autoimmunity against myelin basic protein: CD4+ cells recognizing epitopes of the T cell receptor beta chain from a myelin basic protein-specific T cell clone.

Authors:  G Saruhan-Direskeneli; F Weber; E Meinl; M Pette; G Giegerich; A Hinkkanen; J T Epplen; R Hohlfeld; H Wekerle
Journal:  Eur J Immunol       Date:  1993-02       Impact factor: 5.532

9.  Endocytosis of the TCR/CD3 complex and the class-I major histocompatibility complex in a human T cell line.

Authors:  Y Yamane; M Perez; R Edelson; N Agostino; B Pernis
Journal:  Cell Immunol       Date:  1991-09       Impact factor: 4.868

10.  Antiidiotypic immunity in interstitial nephritis. II. Rats developing anti-tubular basement membrane disease fail to make an antiidiotypic regulatory response: the modulatory role of an RT7.1+, OX8- suppressor T cell mechanism.

Authors:  E G Neilson; E McCafferty; S M Phillips; M D Clayman; C J Kelly
Journal:  J Exp Med       Date:  1984-04-01       Impact factor: 14.307

View more
  8 in total

1.  Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.

Authors:  Mads Hald Andersen
Journal:  J Natl Cancer Inst       Date:  2015-06-10       Impact factor: 13.506

2.  Activated rat T cells synthesize and express functional major histocompatibility class II antigens.

Authors:  C P Broeren; M H Wauben; M A Lucassen; M Van Meurs; P J Van Kooten; C J Boog; E Claassen; W Van Eden
Journal:  Immunology       Date:  1995-02       Impact factor: 7.397

3.  Immunization with T cell receptor V beta chain peptides deletes pathogenic T cells and prevents the induction of collagen-induced arthritis in mice.

Authors:  T M Haqqi; X M Qu; D Anthony; J Ma; M S Sy
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

Review 4.  TCR peptide therapy in human autoimmune diseases.

Authors:  A A Vandenbark; E Morgan; R Bartholomew; D Bourdette; R Whitham; D Carlo; D Gold; G Hashim; H Offner
Journal:  Neurochem Res       Date:  2001-06       Impact factor: 3.996

5.  Anti-T-cell humoral and cellular responses in healthy BALB/c mice following immunization with ovalbumin or ovalbumin-specific T cells.

Authors:  Xiao-Yu Zhang; Xiang-Guo Liu; Wei Wang; Wen-Chao Wang; Xiao-Ming Gao
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

Review 6.  Insights into the immunopathogenesis of multiple sclerosis.

Authors:  Niels Hellings; Jef Raus; Piet Stinissen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

7.  Structural analysis of the rat T-cell receptor Tcra V4 gene family.

Authors:  M Stangel; G Giegerich; N E Torres-Nagel; T Hünig; H P Hartung
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

8.  Vaccination against autoimmune diseases moves closer to the clinic.

Authors:  Willem van Eden
Journal:  Hum Vaccin Immunother       Date:  2019-04-22       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.